bluuebunny/crossref_metadata_2025_split huggingface dataset:
Clinical Validation of the Nursing Diagnosis, Decreased Cardiac Tissue Perfusion, in Patients with Coronary Artery Obstruction
Authors: Gonçalves Julia Leme , Giovanini Laís Pereira , Lopes Juliana de Lima , Cornélio Marilia Estevão , Lopes Marcos Venícios de Oliveira , Oliveira‐Kumakura Ana Railka de Souza 
Published: January 2020

ABSTRACTOBJECTIVETo verify the accuracy of the nursing diagnosis, decreased cardiac tissue perfusion, in patients with coronary artery disease.METHODSClinical validation consisted of evaluation by 75 participants. Sensitivity and specificity measurements were performed by means of latent class analysis.RESULTSThe prevalence of the diagnosis was 64.5%. Nausea, dizziness, and vomiting were sensitive and specific; altered heart rate was specific.CONCLUSIONFour indicators were accurate for the nursing diagnosis.IMPLICATIONS FOR NURSINGAccurate defining characteristics contribute to reliable and precise assessment and enable nurses to diagnose and intervene in the outcome of the patient's clinical condition.
Recent cannabis use is associated with smaller hippocampus volume: High‐resolution segmentation of structural subfields in a large non‐clinical sample
Authors: Owens Max M. , Sweet Lawrence H. , MacKillop James 
Published: January 2020

AbstractThere is mixed evidence that individuals who use cannabis have reduced hippocampal and amygdalar gray matter volume, potentially because of small sample sizes and imprecise morphological characterization. New automated segmentation procedures have improved the measurement of these structures and allow better examination of their subfields, which have been linked to distinct aspects of memory and emotion. The current study applies this new segmentation procedure to the Human Connectome Project Young Adult dataset (N = 1080) to investigate associations of cannabis use with gray matter volume in the hippocampus and amygdala. Results revealed significant bilateral inverse associations of hippocampal volume with recent cannabis use (THC+ urine drug screen; P < .005). Hippocampal subfield analyses indicated these associations were primarily driven by the head of the hippocampus, the first section of the cornu amonis (CA1), the subicular complex, and the molecular layer of the hippocampus. No associations were detected for age of cannabis initiation, the frequency of cannabis use across the lifespan, or the lifetime presence of cannabis use disorder. In one of the largest studies to date, these results support the hypothesis that recent cannabis use is linked to reduced hippocampal volume, but that this effect may dissipate following prolonged abstinence. Furthermore, these results clarify the specific subfields which may be most associated with recent cannabis use.
Correlation between work impairment, scores of rhinitis severity and asthma using the MASK‐air®App
Authors: Bédard Annabelle , Antó Josep M. , Fonseca Joao A. , Arnavielhe Sylvie , Bachert Claus , Bedbrook Anna , Bindslev‐Jensen Carsten , Bosnic‐Anticevich Sinthia , Cardona Victoria , Cruz Alvaro A. , Fokkens Wytske J. , Garcia‐Aymerich Judith , Hellings Peter W. , Ivancevich Juan C. , Klimek Ludger , Kuna Piotr , Kvedariene Violeta , Larenas‐Linnemann Désirée , Melén Erik , Monti Ricardo , Mösges Ralf , Mullol Joaquim , Papadopoulos Nikos G. , Pham‐Thi Nhân , Samolinski Boleslaw , Tomazic Peter V. , Toppila‐Salmi Sanna , Ventura Maria Teresa , Yorgancioglu Arzu , Bousquet Jean , Pfaar Oliver , Basagaña Xavier ,   the MASK study group
Published: January 2020

AbstractBackgroundIn allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK‐air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom‐medication scores obtained concurrently.MethodsAll consecutive MASK‐air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self‐assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom‐medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra‐individual response variability (IRV) index was calculated.ResultsA strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures.ConclusionsVAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom‐medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies.
Coexistence of nasal reactivity to allergens with and without IgE sensitization in patients with allergic rhinitis
Authors: Eguiluz‐Gracia Ibon , Fernandez‐Santamaria Ruben , Testera‐Montes Almudena , Ariza Adriana , Campo Paloma , Prieto Ana , Perez‐Sanchez Natalia , Salas Maria , Mayorga Cristobalina , Torres Maria Jose , Rondon Carmen 
Published: January 2020

AbstractBackgroundAllergic rhinitis (AR) and local allergic rhinitis (LAR) are defined by nasal reactivity to aeroallergens with and without positive skin prick test (SPT), respectively. In this study, we aimed to investigate whether both types of allergen‐specific reactivity can coexist in the same individual.MethodsForty‐eight patients with perennial rhinitis symptoms and positive SPT with seasonal allergens only (discrepant group) were subjected to consecutive nasal allergen challenges (NAC) with seasonal (NAC‐S) and perennial allergens (NAC‐P). A nasal lavage was collected before and after the NACs to measure eosinophil cationic protein (ECP). A basophil activation test (BAT) with seasonal and/or perennial allergens was performed in ten patients from the discrepant group and in six seasonal allergic rhinitis (SAR), eight perennial local allergic rhinitis (LAR), six nonallergic rhinitis (NAR), and six healthy control (HC) individuals.ResultsAll patients in the discrepant group tested positive in the NAC‐S, and 41 of them (85.4%), also in the NAC‐P (group A). Conversely, seven patients tested negative in the NAC‐P (group B). ECP in the nasal lavage increased after the NAC‐P in the group A (P = .004), but not in the group B. The BAT with seasonal allergens was positive in 100% of SAR and group A cases, whereas the BAT with perennial allergens was positive in 37.5% and 60% of LAR and group A cases, respectively. All NAR and HC subjects tested negative for the BAT.ConclusionThis study shows that nasal reactivity to aeroallergens with and without positive SPT can coexist in the same patient. We propose the term dual allergic rhinitis for this rhinitis phenotype.
Ex situ hypothermic perfusion of nonhuman primate pancreas: A feasibility study
Authors: Prudhomme Thomas , Renaudin Karine , Lo Faro Maria Letizia , Cantarovich Diego , Kervella Delphine , Minault David , Hervouet Jérémy , Le Bas‐Bernardet Stéphanie , Karam Georges , Blancho Gilles , Branchereau Julien 
Published: January 2020

AbstractPancreatic static cold storage (SCS) is the gold‐standard method for pancreas preservation. Our main objective was to evaluate feasibility of hypothermic perfusion (HP) of nonhuman primates’ pancreases for potential organ transplantation. Seven baboon pancreases were tested. Animals were included in a study approved by the French Research Ministry of Health. Two groups were compared: the control group (n = 2) was preserved using conventional SCS for 24‐h and the perfusion group (n = 5) used HP for 24‐h, with three different perfusion pressures (PP): 15 (n = 3), 20 (n = 1), and 25 mm Hg (n = 1). In the control group, focal congestion of islets was observed after 6‐h. At 24‐h, ischemic necrosis and multifocal congestion also occurred. In the HP group, at 15 mm Hg PP, multifocal congestion of islets was present at 24‐h. At 20 mm Hg PP, no ischemic necrosis was found after 6‐h. At 12‐h and 24‐h, focal congestion of islets was seen. At 25 mm Hg PP, focal congestion of islets appeared after 12‐h. Immunostaining for insulin, glucagon, and somatostatin was normal and similar in controls and perfused pancreas transplants even after 24‐h. Apoptosis index represented by cleaved caspase 3 activity, was less than 1% in perfusion and control groups, even after 24‐h. HP of nonhuman primate pancreas is feasible and not deleterious as far as 24‐h compared to SCS. SCS for more than 12‐h was harmful for the transplants. Systolic perfusion pressure between 15‐20 mm Hg did not cause any pathological injury of the tested organs.
The importance of cytokines analysis in the diagnosis of vitreoretinal lymphoma
Authors: Frenkel Shahar , Pe'er Jacob , Kaufman Ron , Maly Bella , Habot‐Wilner Zohar 
Published: January 2020

AbstractPurposeTo evaluate the efficacy of the different diagnostic tests for vitreoretinal lymphoma (VRL).MethodsA cohort of 150 patients with a presumed diagnosis of VRL. Vitrectomy samples were analysed for cytology, monoclonality [polymerase chain reaction (PCR)] and cytokine levels, and anterior chamber taps were analysed for cytokine levels. Vitreoretinal lymphoma (VRL) was diagnosed after confirming the clinical suspicion with vitreal or brain cytology.ResultsVitreoretinal lymphoma (VRL) was diagnosed in 78 patients. Vitreal cytology was positive for 53/132 patients (40.2%), 36/53 had positive cytology from both the eye and the brain. Additional 25 patients had positive brain cytology. Vitreal PCR for monoclonality was positive for 32/91 patients (35.2%). Vitreal cytokine levels of interleukin (IL)‐10/IL‐6 were >1 for 47/110 patients (43.1%). For cytology, PCR and cytokine analysis, the respective sensitivity was 73.6%, 46.0% and 81.4%, and the accuracy of the tests was 85.6%, 60.4% and 80.9%, respectively. All three tests were available for 79 patients. In this subset, for cytology, PCR and cytokine analysis the respective sensitivity was 79.5%, 41.0% and 82.1%, respectively, and the accuracy of the tests was 89.9%, 60.8% and 81.0%, respectively.ConclusionCytokines analysis has an important role in the diagnosis of VRL. We suggest analysing cytokines levels in all cases suspected of VRL along with cytology and PCR analysis.
Electrolyte and transporter responses to angiotensin II induced hypertension in female and male rats and mice
Authors: Veiras Luciana C. , McFarlin Brandon E. , Ralph Donna L. , Buncha Vadym , Prescott Jessica , Shirvani Borna S. , McDonough Jillian C. , Ha Darren , Giani Jorge , Gurley Susan B. , Mamenko Mykola , McDonough Alicia A. 
Published: January 2020

AbstractAimSexual dimorphisms are evident along the nephron: Females (F) exhibit higher ratios of renal distal to proximal Na+ transporters' abundance, greater lithium clearance (CLi) more rapid natriuresis in response to saline infusion and lower plasma [K+] vs. males (M). During angiotensin II infusion hypertension (AngII‐HTN) M exhibit distal Na+ transporter activation, lower proximal and medullary loop transporters, blunted natriuresis in response to saline load, and reduced plasma [K+]. This study aimed to determine whether responses of F to AngII‐HTN mimicked those in M or were impacted by sexual dimorphisms evident at baseline.MethodsSprague Dawley rats and C57BL/6 mice were AngII infused via osmotic minipumps 2 and 3 weeks, respectively, and assessed by metabolic cage collections, tail‐cuff sphygmomanometer, semi‐quantitative immunoblotting of kidney and patch‐clamp electrophysiology.ResultsIn F rats, AngII‐infusion increased BP to 190 mm Hg, increased phosphorylation of cortical NKCC2, NCC and cleavage of ENaC two to threefold, increased ENaC channel activity threefold and aldosterone 10‐fold. K+ excretion increased and plasma [K+] decreased. Evidence of natriuresis in F included increased urine Na+ excretion and CLi, and decreased medullary NHE3, NKCC2 and Na,K‐ATPase abundance. In C57BL/6 mice, AngII‐HTN increased abundance of distal Na+ transporters, suppressed proximal‐medullary transporters and reduced plasma [K+] in both F and M.ConclusionDespite baseline sexual dimorphisms, AngII‐HTN provokes similar increases in BP, aldosterone, distal transporters, ENaC channel activation and K+ loss accompanied by similar suppression of proximal and loop Na+ transporters, natriuresis and diuresis in females and males.
EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B‐cell lymphoma
Authors: Neves Filho Eduardo Henrique , Hirth Carlos Gustavo , Frederico Igor Allen , Burbano Rommel Mario , Carneiro Thiago , Rabenhorst Silvia Helena 
Published: January 2020

EZH2 is an important epigenetic regulator, but its role in diffuse large B‐cell lymphoma (DLBCL) pathogenesis and its relationship with MYC, BCL2, and TP53 expression, chromosomal rearrangements, and clinical features are still poorly understood. So, we investigated EZH2 expression and its associations with the immunophenotypic presentations, including MYC, BCL2, and TP53 expression, MYC, BCL2, and BCL6 translocation status, clinicopathological features, and therapeutic response to R‐CHOP in a series of 139 DLBCL cases. EZH2 positivity was associated with MYC and TP53 expression (p = 0.0002 and p = 0.0000, respectively) and to high proliferative index (Ki67>70%, p = 0.0082). No associations were found among EZH2 expression and chromosomal translocation status. The non‐germinal center (nGC) DLBCL presented most of associations observed in the general sample; however, only TP53 immunodetection showed associations with EZH2 expression in the germinal center (GC) DLBCL. EZH2 expression had no impact on therapeutic efficacy in R‐CHOP‐treated patients. In conclusion, EZH2 seems to be upregulated by MYC, to rely on TP53 alterations, and is associated with high proliferative tumors in DLBCL, which might be dependent on GC or nGC subclassifications. Furthermore, it is not a therapeutic efficacy marker to R‐CHOP in our series.
Five‐year survival follow‐up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine‐refractory chronic lymphocytic leukaemia: a short report
Authors: Miklos Udvardy , Strugov Vladimir , Lewerin Catharina , Grosicki Sebastian , Mazur Grzegorz , Steurer Michael , Montillo Marco , Kryachok Irina , Middeke Jan M. , Rekhtman Grygoriy , Stefanelli Tommaso , Vincent Ghislaine , Govindaraju Sameera , Österborg Anders 
Published: January 2020

SummaryIn 2014, an interim analysis of a phase 3 study was performed to evaluate the effectiveness of ofatumumab in patients with bulky fludarabine‐refractory chronic lymphocytic leukaemia (BFR CLL) as compared to physician’s choice. The five‐year follow‐up of this phase 3 trial showed that ofatumumab therapy resulted in a numerically but not significantly longer overall survival. As only few patients had the chance to receive a kinase inhibitor later, the study displays the survival of BFR CLL patients in the period prior to receiving small‐molecule inhibitors. Ofatumumab is a well‐tolerable treatment option in multiresistant advanced CLL.
Efficacy of vibegron, a novel β3‐adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo‐controlled, double‐blind, comparative phase 3 study
Authors: Yoshida Masaki , Takeda Masayuki , Gotoh Momokazu , Yokoyama Osamu , Kakizaki Hidehiro , Takahashi Satoru , Masumori Naoya , Nagai Shinji , Minemura Kazuyoshi 
Published: January 2020

ObjectiveTo evaluate the efficacy of a novel and selective β3‐adrenoreceptor agonist vibegron on urgency urinary incontinence (UUI) in patients with overactive bladder (OAB).Patients and MethodsA post hoc analysis was performed in patients with UUI (>0 episodes/day) who were assigned to receive vibegron or placebo in a vibegron phase 3 study. Patients were subclassified into mild/moderate (>0 to <3 UUI episodes/day) or severe UUI (≥3 UUI episodes/day) subgroup. Changes from baseline in number of UUI episodes/day, in number of urgency episodes/day, and in voided volume/micturition were compared between the groups. The percentage of patients who became UUI‐free ('diary‐dry' rate) and the response rate (percentage of patients with scores 1 [feeling much better] or 2 [feeling better] assessed by the Patient Global Impression scale [PGI]) were evaluated.ResultsChanges in numbers of UUI episodes at week 12 in the vibegron 50 mg, vibegron 100 mg and placebo groups, respectively, were −1.35, −1.47 and −1.08 in all patients, −1.04, −1.13 and −0.89 in the mild/moderate UUI subgroup, and −2.95, −3.28 and −2.10 in the severe UUI subgroup. The changes were significant in the vibegron 50 and 100 mg groups vs placebo regardless of symptom severity. Change in number of urgency episodes/day was significant in the vibegron 100 mg group vs placebo in all patients and in both severity subgroups. In the vibegron 50 mg group, a significant change vs placebo was observed in all patients and in the mild/moderate UUI subgroup. Change in voided volume/micturition was significantly greater in the vibegron 50 and 100 mg groups vs placebo in all patients, as well as in the both severity subgroups. Diary‐dry rates in the vibegron 50 and 100 mg groups were significantly greater vs placebo in all patients and in the mild/moderate UUI subgroup. In the severe UUI subgroup, however, a significant difference was observed only in the vibegron 50 mg group. Response rates assessed by the PGI were significantly higher in the vibegron groups vs placebo in all patients and in the both severity subgroups. Vibegron administration, OAB duration ≤37 months, mean number of micturitions/day at baseline <12.0 and mean number of UUI episodes/day at baseline <3.0 were identified as factors significantly associated with normalization of UUI.ConclusionsVibegron, a novel β3‐adrenoreceptor agonist, significantly reduced the number of UUI episodes/day and significantly increased the voided volume/micturition in patients with OAB including those with severe UUI, with the response rate exceeding 50%. These results suggest that vibegron can be an effective therapeutic option for OAB patients with UUI.
Stathmin guides personalized therapy in oral squamous cell carcinoma
Authors: Ju Wu‐tong , Ma Hai‐long , Zhao Tong‐Chao , Liang Si‐yuan , Zhu Dong‐wang , Wang Li‐zhen , Li Jiang , Zhang Zhi‐yuan , Zhou Ge , Zhong Lai‐ping 
Published: January 2020

AbstractThe survival benefit from docetaxel, cisplatin and 5‐fluorouracil (TPF) induction chemotherapy in oral squamous cell carcinoma (OSCC) patients is not satisfactory. Previously, we identified that stathmin, a microtubule‐destabilizing protein, is overexpressed in OSCC. Here, we further investigated its role as a biomarker that impacts on OSCC chemosensitivity. We analyzed the predictive value of stathmin on TPF induction chemotherapy and its impact on OSCC cell chemosensitivity. Then, we further investigated the therapeutic effects of the combination therapy of TPF chemotherapy and PI3K‐AKT‐mTOR inhibitors in vitro and in vivo. We found that OSCC patients with low stathmin expression benefited from TPF induction chemotherapy, while OSCC patients with high stathmin expression could not benefit from TPF induction chemotherapy. Stathmin overexpression promoted cellular proliferation and decreased OSCC cell sensitivity to TPF treatment. In addition, inhibition of the PI3K‐AKT‐mTOR signaling pathway decreased stathmin expression and phosphorylation. The combination therapy of TPF chemotherapy and PI3K‐AKT‐mTOR inhibitors exhibited a potent antitumor effect both in vitro and in vivo. Therefore, stathmin can be used as a predictive biomarker for TPF induction chemotherapy and a combination therapy regimen based on stathmin expression might improve the survival of OSCC patients.
Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway
Authors: Iida Keitaro , Naiki Taku , Naiki‐Ito Aya , Suzuki Shugo , Kato Hiroyuki , Nozaki Satoshi , Nagai Takashi , Etani Toshiki , Nagayasu Yuko , Ando Ryosuke , Kawai Noriyasu , Yasui Takahiro , Takahashi Satoru 
Published: January 2020

AbstractLuteolin is a natural flavonoid with strong anti–oxidative properties that is reported to have an anti–cancer effect in several malignancies other than bladder cancer. In this study, we describe the effect of luteolin on a human bladder cancer cell line, T24, in the context of the regulation of p21, thioredoxin‐1 (TRX1) and the mechanistic target of rapamycin (mTOR) pathway. Luteolin inhibited cell survival and induced G2/M cell‐cycle arrest, p21 upregulation and downregulation of phospho(p)‐S6, which is downstream of mTOR signaling. Luteolin also upregulated TRX1 and reduced intracellular reactive oxygen species production. In a subcutaneous xenograft mouse model using the rat bladder cancer cell line, BC31, tumor volumes were significantly decreased in mice orally administered luteolin compared to control. Immunohistochemical analysis revealed that increased p21 and decreased p‐S6 expression were induced in the luteolin treatment group. Moreover, in another in vivo N‐butyl‐N‐(4‐hydroxybutyl) nitrosamine (BBN)‐induced rat bladder cancer model, the oral administration of luteolin led to a trend of decreased bladder tumor dimension and significantly decreased the Ki67‐labeling index and p‐S6 expression. Furthermore, the major findings on the metabolism of luteolin suggest that both plasma and urine luteolin‐3ʹ‐O‐glucuronide concentrations are strongly associated with the inhibition of cell proliferation and mTOR signaling. Moreover, a significant decrease in the squamous differentiation of bladder cancer is attributed to plasma luteolin‐3ʹ‐glucuronide concentration. In conclusion, luteolin, and in particular its metabolized product, may represent another natural product‐derived therapeutic agent that acts against bladder cancer by upregulating p21 and inhibiting mTOR signaling.